Articles

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or p...

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Record identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5477653

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5477653

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Full title

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2016, Vol.18 (1), p.52-62

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5477653

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

SCOPE AND CONTENTS

Contents

Summary Background High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cance...

ALTERNATIVE TITLES

Full title

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5477653

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5477653

OTHER IDENTIFIERS

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(16)30631-3

How to access this item

Online

1 item

How to access?

Login with a Library card